Shots:
Generian to receive an upfront payment, ~$180M success-based milestone payments & royalties on global net sales of the newly developed products based on the proprietary drug discovery platform for indications with limited treatment options
Under the terms of the agreement, both companies will mutually conduct research & preclinical development activities to identify novel monovalent small molecules after which Astellas will be solely responsible for clinical development, manufacturing & commercialization of the products
Astellas will give the control of discovering small molecule therapies for treatment limited indications to Mitobridge acquired by Astellas on Jan’18
Ref: PR Newswire | Image: Generian
